ArticleCancer medicine2021
Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population-based study.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Distinguishing Second Primary Müllerian Cancer from Breast Cancer Recurrence: Immunohistochemical Pitfalls and a Proposed Diagnostic Algorithm: A Case Report and Literature Review.Cancer management and research · 2026Article
- PERSONALIZED RISK PREDICTION FOR CANCER SURVIVORS: A GENERALIZED BAYESIAN SEMI-PARAMETRIC MODEL OF RECURRENT EVENTS WITH COMPETING OUTCOMES.The annals of applied statistics · 2025Article
- A clinical report and analysis of metachronous multiple primary cancers occurred in four sites.Journal of cancer research and clinical oncology · 2025Article
- Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations.Discover oncology · 2025Review
- Molecule subtypes play important roles for second primary malignancies development based on 324,661 breast cancer survivors.Scientific reports · 2025Article
- Article
- The association between breast cancer and lung cancer: a bidirectional Mendelian randomization study.Scientific reports · 2024Article
- Risk, molecular subtype and prognosis of second primary breast cancer: an analysis based on first primary cancers.American journal of cancer research · 2023Article
- Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis.Frontiers in oncology · 2023Article
- Cancer Prevention for Survivors: Incidence of Second Primary Cancers and Sex Differences-A Population-Based Study from an Italian Cancer Registry.International journal of environmental research and public health · 2022Article
- High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer.Frontiers in oncology · 2022Article
- Relationship between metastasis and second primary cancers in women with breast cancer.Frontiers in oncology · 2022Article
- Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population-based study.Cancer medicine · 2021Article
- Development of a Second Primary Lung Cancer Following a Primary Breast Cancer: A Case Series.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith life span extending, breast cancer (BC) survivors may face the possibility of developing second primary cancer (SPC) and considerably shorten survivorship. However, little is known about multiple primary cancer (MPC) patients with nonmetastatic breast cancer as a first primary malignancy (BCFPM).
methodsHere, we retrospectively analyzed data on cancer survivors with BCFPM diagnosed between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The prognostic factors for breast cancer-specific survival (BCSS) were ascertained by the stepwise regression analysis and a competing risk model, and were integrated to the establishment of prognostic nomogram, of which the accuracy was measured by the calibration curve and the concordance index (C-index).
resultsIn total, 8616 patients were identified with 4.6% of 3-year breast cancer- specific death (BCSD) and 8.6% of 5-year BCSD. The most common SPC among BCFPM patients were female BC and lung cancer. Besides, the median latency time between BC and SPC was 22 months. At a ratio of 7:3, all patients were randomly categorized into a training cohort (n = 6032) and a validation cohort (n = 2584). By a proportional subdistribution hazards regression analysis, the following factors were considered to own independent prognostic abilities of BCSS: subtypes, grade, T classification, N classification, radiation, and sites of SPC. The nomogram could accurately predict 3-year and 5-year breast cancer-associated survival of BCFPM patients with high internal and external validated C-index, 0.715 (95% CI, 0.691-0.739), and 0.683 (95% CI, 0.642-0.724), respectively.
conclusionsBC survivors remained a high risk of developing SPC and considerably shortened survival time. In this study, a favorable nomogram was constructed to as a prediction model for 3-year and 5-year BCSS of BCFPM patients, largely intending to prolong the life of these patients by assisting clinicians to make individualized follow-up plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.